Grant Back. Company shall grant back to Medical School technology rights in UMMC 02-01 entitled “In Vivo Production of siRNAs that Mediate Gene Silencing” in order that Medical School may license to third parties certain intellectual property that Company has declined to license or failed to exercise option rights under terms of the sponsored research agreement referred to in section 3.1(5).
Appears in 4 contracts
Samples: Exclusive License Agreement (Rxi Pharmaceuticals Corp), Exclusive License Agreement (Rxi Pharmaceuticals Corp), Exclusive License Agreement (Cytrx Corp)